Last updated on August 2019

Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma


Brief description of study

To estimate the clinical benefit of cemiplimab monotherapy for patients with metastatic (nodal or distant) cutaneous squamous cell carcinoma (CSCC) (Groups 1 and 3) or with unresectable locally advanced CSCC (Group 2), or with advanced CSCC [metastatic (nodal or distal) or unresectable locally advanced] treated (Group 4) as measured by overall response rate (ORR), according to central review.

Clinical Study Identifier: NCT02760498

Find a site near you

Start Over

Huntsman Cancer Institute

Salt Lake City, UT United States
7.48miles
  Connect »